Novartis has received the FDA approval for its multiple sclerosis (MS) medicine Extavia. The drug has been approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging.